AVITA Medical Inc
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AVITA Medical, Inc. | |
| (Registrant) | |
| Date: February 22, 2024 | /s/ James Corbett |
|---|---|
| James Corbett | |
| Chief Executive Officer (Principal Executive Officer) | |
| Date: February 22, 2024 | /s/ David O'Toole |
| David O'Toole | |
| Chief Financial Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ James Corbett | Chief Executive Officer and Director | February 22, 2024 |
| James Corbett | (Principal Executive Officer) | |
| /s/ David O'Toole | Chief Financial Officer | February 22, 2024 |
| David O'Toole | (Principal Financial and Accounting Officer) | |
| /s/ Lou Panaccio | Chairman of the Board of Directors | February 22, 2024 |
| Lou Panaccio | ||
| /s/ Jeremy Curnock Cook | Director | February 22, 2024 |
| Jeremy Curnock Cook | ||
| /s/ Suzanne Crowe | Director | February 22, 2024 |
| Suzanne Crowe | ||
| /s/ Jan Stern Reed | Director | February 22, 2024 |
| Jan Stern Reed | ||
| /s/ Robert McNamara | Director | February 22, 2024 |
| Robert McNamara | ||
| /s/ Cary Vance | Director | February 22, 2024 |
| Cary Vance | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | ||
| Report of Independent Registered Public Accounting Firm | (PCAOB ID Number 248) | F-2 |
|---|---|---|
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-3 | |
| Consolidated Statements of Operations for the Years-Ended December 31, 2023 and 2022 | F-4 | |
| Consolidated Statements of Comprehensive Loss for the Years-Ended December 31, 2023 and 2022 | F-5 | |
| Consolidated Statements of Stockholders’ Equity for the Years-Ended December 31, 2023 and 2022 | F-6 | |
| Consolidated Statements of Cash Flows for the Years-Ended December 31, 2023 and 2022 | F-7 | |
| Notes to Consolidated Financial Statements | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.